Celldex Therapeutics (CLDX) Total Debt (2010 - 2013)

Celldex Therapeutics' Total Debt history runs 4 years deep, the most recent figure standing at $15.7 million for Q1 2013.

• In Q1 2013, Total Debt rose 3.6% year-over-year to $15.7 million; the TTM figure through Mar 2013 stood at $15.7 million (up 3.6% YoY), while the FY2012 annual figure was $11.3 million, down 25.13% from the prior year.
• Total Debt for Q1 2013 stood at $15.7 million, up from $11.3 million in the prior quarter.
• The five-year high for Total Debt was $19.2 million in Q2 2012, with the low at $10.0 million in Q4 2010.
• The 4-year median for Total Debt is $15.1 million (2011), against an average of $14.4 million.
• The sharpest annual moves came in 2011 and 2012: Total Debt soared 51.44% in 2011, then decreased 25.13% in 2012.
• Celldex Therapeutics' Total Debt stood at $10.0 million in 2010, then jumped by 51.44% to $15.1 million in 2011, then decreased by 25.13% to $11.3 million in 2012, then jumped by 38.74% to $15.7 million in 2013.
• Business Quant data shows CLDX's Total Debt at $15.7 million in Q1 2013, $11.3 million in Q4 2012, and $12.6 million in Q3 2012.